» Articles » PMID: 38441838

Temporal Trends in the Starting of Insulin Therapy in Type 2 Diabetes in Italy: Data from the AMD Annals Initiative

Overview
Publisher Springer
Specialty Endocrinology
Date 2024 Mar 5
PMID 38441838
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Opportunities and needs for starting insulin therapy in Type 2 diabetes (T2D) have changed overtime. We evaluated clinical characteristics of T2D subjects undergoing the first insulin prescription during a 15-year-observation period in the large cohort of the AMD Annals Initiative in Italy.

Methods: Data on clinical and laboratory variables, complications and concomitant therapies and the effects on glucose control after 12 months were evaluated in T2D patients starting basal insulin as add-on to oral/non-insulin injectable agents, and in those starting fast-acting in add-on to basal insulin therapy in three 5-year periods (2005-2019).

Results: We evaluated data from 171.688 T2D subjects who intensified therapy with basal insulin and 137.225 T2D patients who started fast-acting insulin. Overall, intensification with insulin occurred progressively earlier over time in subjects with shorter disease duration. Moreover, the percentage of subjects with HbA1c levels > 8% at the time of basal insulin initiation progressively decreased. The same trend was observed for fast-acting formulations. Clinical characteristics of subjects starting insulin did not change in the three study-periods, although all major risk factors improved overtime. After 12 months from the starting of basal or fast-acting insulin therapy, mean HbA1c levels decreased in all the three investigated time-periods, although mean HbA1c levels remained above the recommended target.

Conclusions: In this large cohort of T2D subjects, a progressively earlier start of insulin treatment was observed during a long observation period, suggesting a more proactive prescriptive approach. However, after 12 months from insulin prescription, in many patients, HbA1c levels were still out-of-target.

References
1.
Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N . Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9 edition. Diabetes Res Clin Pract. 2019; 157:107843. DOI: 10.1016/j.diabres.2019.107843. View

2.
ElSayed N, Aleppo G, Aroda V, Bannuru R, Brown F, Bruemmer D . 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023. Diabetes Care. 2022; 46(Suppl 1):S158-S190. PMC: 9810475. DOI: 10.2337/dc23-S010. View

3.
ElSayed N, Aleppo G, Aroda V, Bannuru R, Brown F, Bruemmer D . 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023. Diabetes Care. 2022; 46(Suppl 1):S140-S157. PMC: 9810476. DOI: 10.2337/dc23-S009. View

4.
Aschner P . Insulin Therapy in Type 2 Diabetes. Am J Ther. 2019; 27(1):e79-e90. DOI: 10.1097/MJT.0000000000001088. View

5.
Russo G, Di Bartolo P, Candido R, Lucisano G, Manicardi V, Giandalia A . The AMD ANNALS: A continuous initiative for the improvement of type 2 diabetes care. Diabetes Res Clin Pract. 2023; 199:110672. DOI: 10.1016/j.diabres.2023.110672. View